Clinical trial
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or…
NCT00003605 · Hoag Memorial Hospital Presbyterian, Other · Withdrawn
Key facts
| NCT number | NCT00003605 |
|---|---|
| Title | Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma |
| Official title | Rituximab Anti-CD20 Monoclonal Antibody Plus Oral Cyclophosphamide as Initial Treatment of Indolent Lymphoma |
| Lead sponsor | Hoag Memorial Hospital Presbyterian, Other |
| Collaborators | Cancer Biotherapy Research Group |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, cyclophosphamide |
| Enrollment | 0 |
| Start date | May 1, 1998 |
| Primary completion | Jan 1, 2000 |
| Completion | Jan 1, 2000 |
| First posted | Aug 4, 2004 |
| Last update posted | Aug 19, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: